Bundesamt für
Verbraucherschutz und
Lebensmittelsicherheit

Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)
Federal Office of Consumer Protection and Food Safety
Mauerstraße 39-42
10117 Berlin
(Germany)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Utertab 2000mg
intrauterine tablet for cattle

aniMedica GmbH

Date: 09 October 2018

MODULE 1

PRODUCT SUMMARY

EU Procedure number	DE/V/0176/001/DC
Name, strength and pharmaceutical form	Utertab 2000mg intrauterine tablet for cattle
Applicant	aniMedica GmbH Im Südfeld 9 48308 Senden-Bösensell Germany
Active substance(s)	Tetracycline hydrochloride
ATC Vetcode	QG51AA02
Target species	Cattle (lactating cow)
Indication for use	For treatment and prevention of post parturient disorders in cattle: for administration following retained foetal membranes and endometritis caused by pathogens susceptible to tetracycline as well as after severe obstetrical procedures (fetotomy, caesarean section).

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicinal Agencies website (www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Application in accordance with Article 13 (3) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	4 July 2018
Date product first authorised in the Reference Member State (MRP only)	n.a.
Concerned Member States for original procedure	BG, ES, HR, HU, IE, IT, NL, PL, PT, SK, UK

I. SCIENTIFIC OVERVIEW

Utertab 2000mg intrauterine tablet for cattle is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species cattle (lactating cow); the slight reactions observed are indicated in the SPC.

The Utertab 2000mg intrauterine tablet for cattle is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The safety and efficacy aspects of this product are identical to the reference product Tetracyclin-HCL Uterus-Stab, 2000 mg, Tablette zur intrauterinen Anwendung für Rinder by aniMedica GmbH, authorised in Germany since 2005 (authorisation number: 6231403.00.00). The initial application for the reference product was assessed before there was a requirement to have a public assessment report, therefore no details in this section are available.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains 2000 mg tetracycline hydrochloride per intrauterine tablet and the excipients microcrystalline cellulose, maize starch, pregelatinised starch, povidone, colloidal anhydrous silica and magnesium stearate.

The container/closure system is white opaque PVC/PE/PVdC blisters sealed with aluminium foil.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

The product is manufactured in accordance with the European Pharmacopoeia and relevant European guidelines.

C. Control of Starting Materials

The active substance is tetracycline hydrochloride, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data and/or certificates of suitability issued by the EDQM have been provided.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site<s> have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13 (3), and bioequivalence with the reference product has been demonstrated, results of safety tests are not required.

The pharmacological and toxicological aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are adequate to ensure safety of the product to users / the environment / consumers.
However, regarding user safety, a warning phrase was added to minimize the risks: *Gloves should be worn during handling*. Some minor changes in the wording were made to be in line with the ABCD format and the latest version of the QRD template.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines>.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the initial predicted environmental concentration in soil (is less than 100 µg/kg.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted as this is an generic application submitted according to Article 13 (3) of Directive 2001/82/EC as amended and bioequivalence with the identical reference product can be assumed.

MRLs

Tetracycline is included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Pharmacologically active substance	**Marker residue**	**Animal Species**	**MRL**	**Target tissues**	**Other provision**	**Therapeutic Classification**
Tetracycline	Sum of parent drug and its 4-epimer	All food-producing species	100 µg/kg 300 µg/kg 600 µg/kg 100 µg/kg 200 µg/kg	Muscle Liver Kidney Milk Eggs	For fin fish the muscle MRL relates to 'muscle and skin in natural proportions'. MRLs for liver and kidney do not apply to fin fish.	Anti-infectious agents/Antibiotics

Withdrawal Periods

Based on the data provided above, withdrawal periods of 10 days for meat and offal in cattle and 96 hours for milk in cattle are justified.

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological, pharmacological and clinical tests are not required. The efficacy claim for this product is equivalent to those of the reference product.

IV.A Pre-Clinical Studies

Tolerance in the Target Species of Animals

This is an application for a generic product. Both products are identical in terms of quality and quantity of the active substances and the excipients. Furthermore, Utertab 2000mg intrauterine tablet for cattle and Tetracyclin-HCL Uterus-Stab, 2000 mg, Tablette zur intrauterinen Anwendung für Rinder show similar impurity profiles. Systemic and local tolerance has been justified. Studies have not been provided. There is no impact expected neither from the active substances nor the excipients.

Resistance

Regarding the resistance documentation of this application, reference was made by the applicant to the reference product. Adequate warnings and precautions including responsible use warnings appear on the product literature. Mechanisms of resistance are listed in the SPC.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicinal Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

<None>